Sera PrognosticsSERA -2.17%70 EBITDA Margin % is -58,600.00% as of Mar. 2026. GuruFocus rates SERA with a GF Score™ of 70/100 and a GF Value™ of $1.86 (Fairly Valued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Sera Prognostics ranks worse than 99.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sera Prognostics's EBITDA for the
three
months ended in Mar. 2026 was $-8.20 Mil. Sera Prognostics's Revenue for the
three
months ended in Mar. 2026 was $0.01 Mil. Therefore, Sera Prognostics's EBITDA margin for the quarter that ended in Mar. 2026 was -58,600.00%.
Sera Prognostics (NAS:SERA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sera Prognostics EBITDA Margin % Related Terms
Sera Prognostics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sera Prognostics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SERA vs ECOR, OM, RTGN: EBITDA Margin % Comparison
For the Medical Devices subindustry, Sera Prognostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a EBITDA Margin % of -58,600.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sera Prognostics and its competitors. According to the industry distribution chart, Sera Prognostics ranks #814 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 99.8%.
Is Sera Prognostics' EBITDA Margin % too high?
Sera Prognostics' current EBITDA Margin % is -58,600.00%. Based on the distribution chart, Sera Prognostics ranks #814 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sera Prognostics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' EBITDA Margin % compare to ECOR and OM?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #814 out of 816 companies for EBITDA Margin %. This places Sera Prognostics in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sera Prognostics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sera Prognostics's current EBITDA Margin % is -58,600.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Fairly Valued. The stock's GF Value™ is $1.86, compared to a current price of $1.84 — trading 1.1% below its estimated fair value. The current EBITDA Margin % is -58,600.00%. Sera Prognostics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sera Prognostics (SERA), the current EBITDA Margin % is -58,600.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be undervalued.
The current stock price of $1.84 is trading 1.1% below its estimated GF Value™ of $1.86.
GuruFocus considers Sera Prognostics to be Fairly Valued.
Key valuation signals for SERA:
EBITDA Margin %: -58,600.00%
GF Value™: $1.86 vs. price of $1.84 (1.1% below fair value)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
70GF Score
Get the complete analysis for SERA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
